Letters sent to healthcare professionals in May 2017

Letters were sent about Pharmalgen (Bee Venom and Wasp Venom) Initial kits, bendamustine (Levact), and ERWINASE.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 21 June 2017

• Therapeutic area: Cancer, Haematology and Immunology and vaccination

In May 2017, letters were sent about:

• Pharmalgen (Bee Venom and Wasp Venom) Initial kits: implementation of serial dilution protocol for up-dosing; risk of dosing errors (see dilution chart)

• Bendamustine (Levact): increased mortality observed when used in non-approved combination treatments or outside approved indications

• ERWINASE: notice of special handling instructions—vials of ERWINASE from batch 182G should be used with a 5-micron filter needle

Article citation: Drug Safety Update volume 10 issue 11, June 2017: 5.

Published 21 June 2017